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In the course of raising high affinity antibodies to penicilloylated bovine Ig 
(BPO-BGG)  in strain 2 guinea pigs by repeated antigenic stimulation over a 
period of 9 mo, it was observed that one animal from a group of seven no longer 
gave a delayed hypersensitivity  skin response when challenged with BPO-BGG. 
Further investigation revealed that the serum of this  animal  (*305) had no 
detectable antibodies to BPO-BGG but possibly possessed strain-specific anti- 
idiotypic antibodies which specifically suppressed BPO-BGG-induced T-cell pro- 
liferation in vitro. The inhibitory activity which was associated with the serum 
of animal *305 was functionally similar to the strain 2 anti-idiotypic antibodies 
(~ strain 2 BPO-BGG) raised by immunizing strain 2 guinea pigs with immuno- 
adsorbent column-purified strain 2 BPO-BGG  (1). This communication com- 
pares the in vitro inhibitory effect of serum *305 with that of ~ strain 2 BPO- 
BGG antiserum. 
Materials and Methods 
Animals.  Guinea pigs of strain 2, 13 (400-600  g) were obtained from the Institut ffir biologisch- 
medizinische Forschung AG, Fiillinsdorf, Switzerland; their phenotype was checked before use by 
lymphocytotoxicity typing as described elsewhere (2). 
Antigens and Immunization of Guinea Pigs.  The immunization procedures have previously, 
been  described  in  detail  (1,  2).  Briefly,  5  mg aspirin  anhydride  (Chemische  Fabrik  Aubing, 
Mfinchen, Germany) were injected intradermally in 0.1 ml dimethyl sulfoxide on days 0, 4, and 8. 
BPO-BGG (100 ~g) and multichain copolymer poly-L-(Tyr, Glu)-poly-vL-Ala-poly-L-Lys [(T, G)-A-- 
L] (5 rag; Miles-Yeda, Rehovot, Israel) dissolved in phosphate-buffered saline (PBS), 0.01 M, pH 
7.4,  and Tris-buffered saline, 0.02 M, pH 8.2, respectively, were emulsified with an equal volume 
of complete Freund's adjuvant (CFA; Difco Laboratories, Detroit, Mich.). On day 0, each animal 
received 0.8 ml of emulsion divided equally among the four foot pads,  strain 2 and  (2  ×  13)F1 
animals were also immunized with a dinitrophenylated copolymer of L-glutamic acid (60%) and L- 
lysine (40%) (DNPT-GL).  The subscript refers to the average number of DNP groups per molecule, 
Strain 13 animals were injected with a  copolymey of L-glutamic acid (50%) and L-tyrosine (50%) 
(GT; Miles Laboratories, Inc., Miles Research Div., Kankakee, Ill.). Solutions of DNPT-GL and GT 
in 0.01 M PBS, pH 7.4,  were emulsified with an equal volume of CFA. Animals were immunized 
with 100 ~g of DNPT-GL or 500 ~tg of GT subcutaneously in multiple sites in the nuchal skin and 
thigh. 
DetectionofContactandDelayed-TypeSkinHypersensitivity.  In all cases the fiank was shaved 
with an electric clipper a few hours before testing. The increase in skin thickness at the reaction 
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site was measured 24 h  after testing with a  caliper (Schnelltaster; Kroeplin, Schiichtern,  Ger- 
many).  Delayed skin reactivity to BPO-BGG was assessed by the intradermal injection into the 
shaved flank of 5 and 50 ~g BPO-BGG in 100 ~1 of PBS (0.01  M, pH 7.4). 
Production ofAntisera.  Strain 13 anti-strain 2 serum was prepared by immunizing strain 13 
guinea pigs with a homogenate of strain 13 lymph node and spleen cells as previously described 
(3). Antisera against strain 2 and strain 13 anti-BPO-BGG were prepared as previously described 
(2). The immune anti-BPO-BGG antibodies were then used as immunogens for the sensitization of 
strain 2 and strain 13 guinea pigs (1). 
Serum *305 was obtained from a  strain 2 guinea pig (*305) which had been immunized with 
BPO-BGG according to the immunization schedule outlined in Table I.  All animals  Ca total of 
seven) were bled (6-8 ml blood) at about 2 wk intervals and their serum used for the preparation of 
anti-BPO-BGG antibody (2). At the end of day 264 one strain 2 animal out of a group of seven no 
longer gave a delayed hypersensitivity skin response when challenged with 50 ~g BPO-BGG. The 
sera of all animals were tested for their ability to inhibit BPO-BGG-induced T-cell proliferation in 
vitro. 
Absorption of  Antisera.  Antisera were mixed with an equal volume of packed lymph node and 
spleen cells (approximately 10  ~ cells/ml of serum) for 4 h at 4°C. Each antiserum was absorbed at 
least three times. The absorbed antisera were centrifuged at 10,00O rpm for 30 min and sterilized 
by Millipore filtration. 
Antibody Determinations.  Antibodies directed against the penicilloyl (BPO) group were deter- 
mined by the neutralization of penicillin-coated T4 bacteriophages as previously described (4). The 
passive hemagglutination technique was used to measure antibodies to bovine Ig (BGG) (5). BGG 
was bound with carbodiimide to sheep erythrocytes as described by Golub et al. (5). 
Cell Preparation 
PERITONEAL EXUDATE  LYMPHOCYTES (PEL).  Guinea pig PEL were purified by passage through 
nylon wool columns (2). For the assay of antigen-induced proliferation, lymphocyte suspensions 
(20 ×  10B/ml) were incubated with either 100 ~g of DNPT-GL and GT or 400 ~g aspiryl ovalbumin 
(ASP-OVA), BPO-BGG, and  iT, G)-A--L/ml of Medium 199 (M-199)  containing 10% heat-inacti- 
vated fetal calf serum. A portion of the cells was also incubated with 10 ~g phytohemagglutinin 
(PHA)/ml of M-199. The cells were pulsed with antigen for 30 min at 37°C, washed three times with 
M-199,  and then cultured at a  cell concentration of 1.25  ×  106/ml.  0.2-ml aliquots of the antigen- 
pulsed PEL (0.25  ×  106 cells) were cultured in round-bottom microtiter plates (Cooke Microtiter 
system; Sterilin LTD, Richmond, Surrey, England) in medium RPMI-1640 (Grand Island Biologi- 
cal Co., Grand Island, N. Y.) supplemented with penicillin (100 U/ml) and streptomycin (100 ~g/ 
ml), adding either 1% normal guinea pig serum or 1% guinea pig antiserum supplemented with 9% 
beat-inactivated fetal calf serum for 72 h at 37°C.  18 h before the termination of the cultures, 0.5 
~Ci  of tritiated  thymidine  (sp  act,  5  Ci/mmol; The  Radiochemical Centre,  Amersham,  Great 
Britain) was added to each well. The cells were harvested with a multiple cell culture harvester 
(Skatron, Lierbyen, Norway), and the radioactivity was measured in a Beckman liquid scintilla- 
tion counter (Beckman Instruments,  Inc., Fullerton,  Calif.). The results are expressed as total 
counts per minute per culture well. 
Results 
Repeated immunization with BPO-BGG (Table I) over a period of about 9 mo, 
resulted in one strain 2 guinea pig (out of a group of seven) becoming unrespon- 
sive when challenged with BPO-BGG in vivo. Whereas the other members of the 
group  gave  intense  4-h  Arthus  and  24-h  delayed skin  reactions  to  50  ~g  of 
intradermally injected BPO-BGG, animal *305 failed to respond. The skin test 
was repeated  10 days later with the  same results.  The  serum of animal  *305 
contained  no  detectable  antibodies  to  either  the  BPO  group  or to  the  BGG 
carrier, whereas the sera of the other strain 2 guinea pigs in the group had high 
antibody titers to both the BPO and the BGG determinants (results not shown). 
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TABLE I 
Immunization Schedule which Resulted in the Appearance (in 
One Strain 2 Guinea Pig Gut of a Group of Seven) of  Antibodies 
with BPG-BGG-Speeifie Anti-Idiotypic Activity 
Antigen administered 
day 
0  500/~g BPO-BGG in CFA (in foot pads) 
13  500/zg BPO-BGG in CFA (in foot pads) 
31  10/zg BPO-BGG (intradermally  [i.d.]) 
44  100/zg BPO-BGG (i.d.) 
72  100 ~g BPO-BGG (i.d.) 
91  100/zg BPO-BGG (i.d.) 
105  50 ~g BPO-BGG (i.d.) 
123  60/~g BPO-BGG (i.d.) 
163  60 pg BPO-BGG (i.d.) 
179  50/zg BPO-BGG (i.d.) 
220  50/~g BPO-BGG (i.d.) 
239  50/zg BPO-BGG (i.d.) 
264  50 ~tg BPO-BGG (i.d.) 
1095 
TABLE II 
Inhibition ofT-Cell Proliferation, by Anti-Idiotypic Serum (d Strain 2 BPO-BGG) and 
Sera from Strain 2 Guinea Pigs Repeatedly Immunized with BPO-BGG, in Primed High 
Dose-Immunized Strain 2 PEL 
Guinea pig serum added* 
Stimulant 
strain 2 
Normal  "301  *302  *303  *304  *305  *307  *308  BPO-BGG 
NIL  874~:  844  466  700  246  292  412  573  774 
PHA  173,386  113,141  68,063  77,723  58,432  67,643  56,512  81,140  120,843 
BPO-BGG  90,738  347  59,919  57,643  63,883  55,250  630  94,921  72,091 
ASP-OVA  125,505  42,024  51,858  47,857  53,939  59,370  49,578  60,520  82,735 
* Final concentration of  serum in culture was 1%. 
$ Results are  expressed as  counts per minute per  culture. Each result represents the  mean of  three  cultures; significantly depressed 
results are underlined. 
induced T-cell proliferation in vitro. As shown in Table II,  serum *305 totally 
suppresses T-cell proliferation, whereas the sera from the other strain 2 guinea 
pigs which gave strong skin responses to BPO-BGG failed to inhibit lymphocyte 
proliferation. The results in Table III further show that serum *305 and h strain 
2 BPO-BGG (raised by immunizing with syngeneic anti-BPO-BGG;) can both 
specifically suppress T-cell activation of primed strain 2 PEL but not of strain 13 
PEL (Table IV). Furthermore, the inhibitory activity of serum *305 can only be 
absorbed  by  immune  cells  from strain  2  (Table  III) guinea  pigs  but  not by 
immune cells from strain 13 animals (Table HI). These data suggest a functional 
similarity between serum *305 and strain-specific strain 2 BPO-BGG. 
Discussion 
A number of recent studies have reported the production of autologous anti- 
idiotypic antibodies (6-9) and it has been suggested (9) that the in vivo appear- 
ance of anti-idiotypic antibodies serves a regulatory function, possibly by con- 
trolling the  synthesis  of a  particular  antibody  elaborated  in response  to an 
antigenic stimulus.  The phenomenon of idiotype-anti-idiotype interactions,  as 
suggested by Jerne (10) and recently modified by Hoffmann (11), is pictured as a 
network of interacting variable domains of immunoglobulin molecules. A simi- 1096  ANDREW  F.  GECZY  BRIEF  DEFINITIVE  REPORT 
TABLE III 
Inhibition of T-Cell Proliferation by Serum *305 and d Strain 2 BPO-BGG in Primed 
Strain 2 PEL: the Absorption of  Inhibitory Activity of  Serum *305 with Immune Strain 2 
Lymphoid Cells 
Stimulant 
Guinea pig serum added* 
strain 2  Normal  13 anti-2  *305 
BPO-BGG 
*305 absorbed  *305  absorbed 
with strain 2  with strain 13 
cells  cells 
NIL  743*  848  909  1080  686  777 
PHA  98,752  102,934  90,743  99,432  93,485  87,491 
DNP.GL  62,504  1,286  60,255  66,466  60,906  50,904 
ASP-OVA  88,908  80,942  81,900  90,801  80,805  81,912 
BPO-BGG  73,462  70,919  1,863  1,846  69,743  1,899 
(T,G)-A-.L  90,754  80,523  72,427  92,629  74,845  62,583 
* See footnote to Table II. 
TABLE IV 
The Failure of Serum *305 to Inhibit In Vitro T-Cell Proliferation in Primed Strain 13 
PEL 
Stimulant 
Guinea pig serum added* 
Normal  2 Anti-13  ~ Strain 13  BPO-BGG  *305 
NIL  505*  308  499  589 
PHA  73,496  60,462  70,625  72,808 
GT  60,808  507  50,805  62,636 
ASP-OVA  45,459  30~  49,753  44,644 
BPO-BGG  38,082  1~263  806  32,805 
(T,G)-A--L  40,976  ~  38,626  41,414 
* See footnote to Table II. 
lar theory based on the interaction of complementary idiotypes has been put 
forward by KShler et al.  (12). 
The results in this paper indicate that a serum with specific in vitro inhibitory 
activity may arise in the course of repeated antigenic stimulation. These data 
are reminiscent of the production of anti-idiotypic antibody in rats repeatedly 
immunized with alloantigens (9). A striking feature of serum *305 however, is 
that its activity appears to be directed against strain-specific idiotypes charac- 
teristic of strain 2 guinea pigs and in this respect serum *305 is functionally 
similar to ~ strain 2 BPO-BGG produced by repeated immunization with synge- 
neic antibodies.  Both serum *305 and  ~  strain  2 BPO-BGG  are exquisitely 
specific  in vitro  in that they only inhibit  BPO-BGG-induced in  vitro T-cell 
proliferation but they do not interfere with the stimulation induced by the other 
antigens (Table HI; reference 1). 
The significance of the production of "auto-anti-idiotypic antibodies", specifi- 
cally reactive with a particular antigen (in one case out of seven), is at present 
not clear. One possibility is that the production of anti-BPO-BGG may have 
been suppressed by an excess of complementary (12) anti-idiotypic antibodies 
with the result that the immune balance in the "suppressed" animal may have 
been temporarily shifted in the favor of auto-anti-idiotypic antibody production. 
Further studies with strain 2 guinea pigs using different immunization sched- 
ules and monitoring the appearance and disappearance of antibodies and anti- 
idiotypic antibodies may clarify this point. 
In support of the  suggestion that the auto-anti-idiotypic antibodies  (8,  9), ANDREW  F.  GECZY  BRIEF  DEFINITIVE  REPORT  1097 
which sometimes appear in the serum of immunologicaily unresponsive ani- 
mals,  may serve  an  immunoregulatory role  is  the  finding that the  in vivo 
administration of ~  strain  2  BPO-BGG  into sensitized strain  2  guinea pigs 
results in a dramatic but short-lived (about 4 wk) fall in the level of anti-BPO 
antibodies. 1 
It remains to be  seen whether further immunization with BPO-BGG can 
induce unresponsiveness in the remaining responders of the group with the 
concomitant appearance of "auto-antibody" activity and whether recovery from 
unresponsiveness results in a decline in the level of BPO-BGG-specific inhibi- 
tory activity in the serum of animal *305. 
Summary 
The in vitro T-cell proliferation induced by penicilloylated bovine IgG (BPO- 
BGG)  in sensitized strain 2  guinea pigs could be  specifically blocked by the 
serum of guinea pig (*305) which had been repeatedly immunized with BPO- 
BGG over a period of 9 mo. The antibodies which appeared in the serum of this 
animal (*305) were functionally similar to the strain 2 anti-idiotypic antibodies 
(~ strain 2 BPO-BGG) raised by immunizing strain 2 guinea pigs with immuno- 
adsorbent column-purified BPO-BGG. Animal *305 had no detectable antibodies 
to BPO-BGG and failed to give a delayed hypersensitivity skin response when 
challenged with BPO-BGG. 
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reading of the manuscript. 
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